Clinical trial
A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC
NCT00923273 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- February 29, 2008
- Completion date
- March 10, 2013
- Enrollment
- 42 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.